Life Sciences in the Antitrust Hot Seat – Key Trends and Guidance for Navigating Increasingly Hostile Waters
Event summary
Conduct by life science companies has long been the subject of intense antitrust scrutiny, with focus in recent years on what some perceive to be high drug prices enabled by anticompetitive acquisitions, sometimes branded as “killer acquisitions” and conduct that prevents or delays generic entry. With the incoming Biden Administration, signs abound that this scrutiny is very likely to reach new levels in 2021 and beyond.
Cooley antitrust lawyers Jacqueline Grise, Tanisha James, Dee Bansal and David Burns will discuss the latest trends relating to antitrust enforcement in life sciences from federal and state enforcers to private plaintiffs and offer guidance for navigating these increasingly hostile waters.
For more information, please email Rebecca Lanz.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.